Menopause is not a disease, and it is not the end of a woman’s strength, beauty or identity. It is a natural biological transition. But for many women, the symptoms are not small. Hot flashes, hot flushes, night sweats, poor sleep, mood changes, anxiety, vaginal dryness, painful intimacy, recurrent urinary symptoms, joint pain, brain fog, weight changes and fear of bone loss can affect confidence, marriage, work, travel, prayer, family life and emotional peace.
This is why menopause hormone therapy research is important. Today, the discussion is no longer simply “HRT is good” or “HRT is dangerous.” Modern menopause care is more personal. The right question is: Which woman, at what age, with which symptoms, with which medical history, needs which treatment, in which dose, route and duration?
Current evidence shows that menopause hormone therapy, also called MHT or HRT, remains the most effective treatment for vasomotor symptoms such as hot flashes, hot flushes and night sweats, and it also helps genitourinary symptoms of menopause and bone health in appropriate women [1]. For many healthy symptomatic women who are younger than 60 or within 10 years of menopause, the benefit-risk balance is considered favourable when there are no contraindications [1].
What menopause hormone research says now
Menopause is clinically diagnosed after 12 consecutive months without a menstrual period. Perimenopause is the transition before menopause, when hormones fluctuate and symptoms may begin. In most women, this transition occurs between the mid-40s and mid-50s, but symptoms can start earlier, especially after surgery, chemotherapy, autoimmune ovarian failure or premature ovarian insufficiency.
The main hormone change is declining ovarian estrogen, along with changes in progesterone and other reproductive hormones. These changes affect the brain’s temperature control, sleep rhythm, vaginal and urinary tissues, bones, skin, mood and metabolism. This is why one woman may suffer mainly from night sweats, while another may struggle with vaginal dryness, anxiety, poor concentration or body aches.
The strongest evidence for systemic HRT is relief of hot flashes, hot flushes and night sweats. The North American Menopause Society states that hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, and that it helps prevent bone loss and fracture [1]. NICE in the UK recommends offering HRT for vasomotor symptoms associated with menopause, while also recognising menopause-specific cognitive behavioural therapy as an option alongside HRT, when HRT is unsuitable, or when a person prefers not to use HRT [2].
The Women’s Health Initiative changed the public conversation around HRT in 2002, but later analysis has shown that the original fear became oversimplified. A 2024 JAMA review explains that WHI results do not support using menopausal hormone therapy to prevent cardiovascular disease, dementia or other chronic diseases in postmenopausal women. However, the same review confirms that menopausal hormone therapy is appropriate for treating bothersome vasomotor symptoms in women in early menopause who have no contraindications and want treatment [3].
Who may benefit most from HRT or MHT
The woman most likely to benefit from menopause hormone therapy is usually under 60, within 10 years of menopause, and significantly troubled by hot flashes, night sweats, sleep disruption, menopause-related mood changes, vaginal symptoms or early bone loss risk. She should also have no major contraindications [1].
For women with premature ovarian insufficiency or early menopause, HRT can be especially important. Estrogen deficiency at a younger age may increase long-term risks for bone loss, cardiovascular issues and emotional symptoms. NICE advises that people with premature ovarian insufficiency should be offered hormonal treatment with HRT or a combined hormonal contraceptive until at least the age of natural menopause, unless contraindicated [2].
Women who have a uterus usually need estrogen plus a progestogen to protect the womb lining. Women who have had a hysterectomy may often use estrogen alone, unless there is another specific reason to add a progestogen. Women with mainly vaginal dryness, burning, painful sex or urinary symptoms may not need full-body hormone therapy and may benefit from local vaginal estrogen or other local treatments [2].
This is an important message for women who silently suffer from vaginal dryness or painful intimacy. Many think they must accept it as ageing, or they feel too shy to discuss it. But genitourinary syndrome of menopause is common, treatable and medically recognised. NICE recommends vaginal oestrogen for genitourinary symptoms and explains that serious adverse effects are very rare because absorption into the body is minimal compared with systemic HRT [2].
The risks women deserve to understand clearly
The safest menopause care is not based on fear, and it is not based on blind confidence. It is based on individual assessment.
HRT may not be suitable for women with a history of breast cancer, certain uterine cancers, unexplained vaginal bleeding, active or previous blood clots, stroke, active liver disease or complex cardiovascular risks. These women need specialist advice before using systemic hormone therapy [1,2].
Breast cancer risk depends on the type of HRT and duration of use. The risk is not the same for estrogen-only therapy and combined estrogen-progestogen therapy. The Menopause Society explains that breast cancer risk does not increase appreciably with short-term estrogen-progestogen therapy and may be decreased with estrogen alone, while also recognising that longer duration may carry a rare potential risk [1]. A large 2024 Norwegian cohort study found that breast cancer associations varied by hormone therapy type and drug, with oral estrogen combined with daily progestin showing the highest risk in that study, while vaginal estradiol was not associated with breast cancer risk [10].
Blood clot and stroke risk also depend on route. Oral estrogen can affect clotting pathways more than transdermal estrogen. Transdermal HRT through patches, gels or sprays may reduce the risk of venous thromboembolism and stroke in some women [1]. NICE advises considering transdermal rather than oral HRT for people at increased risk of venous thromboembolism, including those with BMI over 30 kg/m² [2].
This is why the decision should not be “HRT yes or no” only. A better question is: Which route, which dose, which hormone combination and which safety review is best for this woman?
New non-hormonal menopause treatments
Menopause care has moved beyond hormones alone. Some women cannot take HRT. Some prefer not to take it. Some have breast cancer history, clotting risks, liver concerns or personal reasons. For these women, newer non-hormonal medicines are changing the treatment landscape.
In 2023, the U.S. FDA approved fezolinetant, a non-hormonal neurokinin 3 receptor antagonist, for moderate to severe hot flashes caused by menopause [4]. NICE’s 2026 technology appraisal recommends fezolinetant as an option for moderate to severe vasomotor symptoms when HRT is unsuitable [6].
In 2025, the FDA prescribing label listed Lynkuet, elinzanetant, for the treatment of moderate to severe vasomotor symptoms due to menopause [5]. Elinzanetant is a hormone-free neurokinin receptor antagonist, and availability may vary by country. Health Canada also authorised Lynkuet for moderate to severe vasomotor symptoms associated with menopause [9].
These new medicines do not make HRT outdated. They make menopause care more complete. The best approach may include HRT, vaginal estrogen, non-hormonal medicine, CBT, pelvic floor therapy, nutrition, exercise, yoga, Ayurveda-informed daily routine or a careful combination.
Why this matters for women in the USA, UK, Singapore, Canada and Australia
Menopause awareness is rising globally, but many women are still undertreated. In the USA, the conversation is shifting from fear-based HRT avoidance to personalised risk assessment. In the UK, NICE guidance supports offering HRT for vasomotor symptoms and recognises additional options such as CBT and fezolinetant when suitable [2,6]. In Singapore, KKH and MCHRI launched Singapore’s first menopause management guidelines in 2026, highlighting clinical diagnosis in women over 45 based on history and reaffirming the safety and efficacy of menopause hormone therapy in appropriate women [7]. In Canada, guidance supports initiating hormone therapy generally in women under 60 or within 10 years of menopause when there are no contraindications [8]. In Australia, menopause societies and clinicians increasingly emphasise individualised MHT, safe prescribing and caution against unregulated compounded hormones [1].
The message is clear across modern menopause medicine: women should not be dismissed, frightened or left to suffer. They deserve evidence-based options, privacy, respect and follow-up.
How Ayurveda helps during menopause
Ayurveda views menopause as a natural life transition, not as a disease. In Ayurvedic understanding, midlife is a time when Vata tends to increase. This may be experienced as dryness, lighter sleep, anxiety, joint discomfort, constipation, irregular digestion, nervous sensitivity and fatigue. Pitta may also show through heat, sweating, irritability, acidity and disturbed sleep. Dhatu kshaya, or gradual tissue depletion, may be understood as reduced nourishment, dryness, bone weakness, skin changes and low vitality.
This Ayurvedic view is powerful because it does not reduce a woman to one hormone level. It looks at digestion, sleep, stress, tissues, dryness, heat, strength, mind and lifestyle. Ayurveda helps menopause care become more human.
A good Ayurvedic menopause plan may include warm nourishing food, regular meal timing, digestion support, sleep routine, oil massage, yoga, pranayama, meditation, Rasayana support, stress reduction and carefully selected herbs. It should not claim to reverse menopause. It should not replace HRT when HRT is medically needed. Instead, Ayurveda can support the woman’s whole system so she feels grounded, nourished and steady.
Modern research is beginning to explore some Ayurvedic botanicals. A 2025 randomized, double-blind, placebo-controlled study reported that Ashwagandha and Shatavari extracts reduced menopause symptoms, vascular dysfunction and bone turnover markers in postmenopausal women [14]. Another 2025 randomized study on Shatavari root extract reported improvement in menopausal symptoms, including hot flashes, mood and quality-of-life measures [15]. These studies are promising, but herb quality, dose, patient selection and safety monitoring matter.
Yoga also has growing evidence. A 2025 systematic review and meta-analysis of randomized controlled trials found that yoga improved overall menopausal symptoms, sleep quality, anxiety, depressive symptoms, BMI and blood pressure, although effects on hot flashes were not always significant compared with usual care [16].
This is where integrative menopause care becomes convincing. HRT may quickly reduce hot flashes and night sweats in suitable women. Ayurveda, yoga, food, sleep care and stress regulation can support digestion, sleep, nervous system balance, dryness, mood and long-term vitality. Together, they can help a woman feel that menopause is not a collapse, but a new phase of strength.
Ayurvedic shlokas for menopause care and healing
Book: Charaka Samhita
Section: Sutra Sthana
Chapter: 1, Deerghanjiviteeya Adhyaya
Text: 41
Sanskrit:
हिताहितं सुखं दुःखमायुस्तस्य हिताहितम् ।
मानं च तच्च यत्रोक्तमायुर्वेदः स उच्यते ॥४१॥
Transliteration:
hitāhitaṃ sukhaṃ duḥkham āyus tasya hitāhitam |
mānaṃ ca tacca yatroktam āyurvedaḥ sa ucyate || 41 ||
Translation:
Ayurveda is the knowledge that explains beneficial and harmful life, happy and unhappy life, what supports or harms life, and the measure of life [12].
Menopause meaning: This shloka is important because menopause care is not only about stopping symptoms. It is about understanding what is beneficial or harmful for this woman’s life, body, mind, sleep, marriage, confidence and long-term health.
Book: Charaka Samhita
Section: Chikitsa Sthana
Chapter: 1, Rasayana Adhyaya
Text: 7–8
Sanskrit:
दीर्घमायुः स्मृतिं मेधामारोग्यं तरुणं वयः ।
प्रभावर्णस्वरौदार्यं देहेन्द्रियबलं परम् ॥७॥
वाक्सिद्धिं प्रणतिं कान्तिं लभते ना रसायनात् ।
लाभोपायो हि शस्तानां रसादीनां रसायनम् ॥८॥
Transliteration:
dīrgham āyuḥ smṛtiṃ medhām ārogyaṃ taruṇaṃ vayaḥ |
prabhā-varṇa-svaraudāryaṃ dehendriya-balaṃ param || 7 ||
vāksiddhiṃ praṇatiṃ kāntiṃ labhate nā rasāyanāt |
lābhopāyo hi śastānāṃ rasādīnāṃ rasāyanam || 8 ||
Translation:
Through Rasayana, a person gains long life, memory, intelligence, health, youthful vitality, radiance, voice quality and strength of body and senses [13].
Menopause meaning: Rasayana in menopause should be understood as rejuvenative support through food, lifestyle, conduct, herbs and medical guidance. It should not be marketed as a miracle anti-ageing promise. Its true value is nourishment, resilience and graceful ageing.
Book: Ashtanga Hridaya
Section: Sutra Sthana
Chapter: 2, Dinacharya Adhyaya
Text: 8
Sanskrit:
अभ्यङ्गमाचरेन्नित्यं स जराश्रमवातहा ।
दृष्टिप्रसादपुष्ट्यायुःस्वप्नसुत्वक्त्वदार्ढ्यकृत् ॥८॥
शिरःश्रवणपादेषु तं विशेषेण शीलयेत् ॥
Transliteration:
abhyaṅgam ācaret nityaṃ sa jarā-śrama-vātahā |
dṛṣṭi-prasāda-puṣṭy-āyuḥ-svapna-sutvaktva-dārḍhya-kṛt || 8 ||
śiraḥ-śravaṇa-pādeṣu taṃ viśeṣeṇa śīlayet ||
Translation:
Daily oil massage is described as helpful for ageing, fatigue, Vata, sleep, nourishment, skin quality and body firmness, especially when applied to the head, ears and feet [17].
Menopause meaning: For women with dryness, poor sleep, anxiety, fatigue and body aches, Abhyanga can be a deeply grounding practice when suitable. It should be avoided or modified in fever, indigestion, acute illness or when advised by a clinician.
A message for Gulf, Arabic and Urdu speaking patients
Arabic lipi:
سنّ اليأس ليس نهاية الأنوثة، بل مرحلة طبيعية من النضج والقوة. العلاج الهرموني قد يساعد بعض النساء كثيراً في الهبّات الساخنة، التعرّق الليلي، النوم، جفاف المهبل وصحة العظام، ولكن القرار يجب أن يكون بعد تقييم طبي دقيق وباحترام الخصوصية، الحياء، الدين، الأسرة ونمط الحياة.
Urdu lipi:
مینوپاز عورت کی کمزوری نہیں، زندگی کا ایک قدرتی اور باوقار مرحلہ ہے۔ ہارمون تھراپی ہر عورت کے لیے ضروری نہیں، لیکن صحیح مریضہ میں، صحیح وقت پر، ڈاکٹر کے مشورے سے، یہ نیند، ہاٹ فلیشز، موڈ، ہڈیوں، ازدواجی زندگی اور اعتماد میں بہت مدد دے سکتی ہے۔
Gulf patients often want discreet, respectful and family-sensitive care. Many women feel shy discussing vaginal dryness, painful intimacy, urinary symptoms or mood changes. A good menopause consultation should protect privacy, respect modesty, understand fasting and prayer routines, and offer a female-friendly environment where possible.
Menopause care should never make a woman feel embarrassed. Whether she chooses HRT, non-hormonal treatment, Ayurveda, local vaginal therapy, nutrition, yoga or a combination, she deserves clear explanation, safe follow-up and dignity.
What a safe integrative menopause plan looks like
A safe menopause plan begins with listening. The clinician should ask about age, periods, symptoms, uterus status, contraception needs, migraine, blood pressure, diabetes, clot history, breast symptoms, cancer history, liver disease, family history, medications, smoking, weight, sleep, mood, sexual pain and bone risk.
Blood tests are not always required for typical menopause diagnosis after age 45, but they may be useful in early menopause, premature ovarian insufficiency, complex symptoms or unclear cases [2].
If HRT is suitable, the plan should use the right dose, route and duration for the woman’s symptoms and risk profile, with regular review [1]. If the uterus is present, progesterone protection is usually required with systemic estrogen. If clot risk is higher, transdermal estrogen may be preferred. If symptoms are mainly vaginal or urinary, local vaginal estrogen may be enough [2].
Ayurveda can be added safely when it is supervised. Shatavari, Ashwagandha, Amalaki, Brahmi, Guduchi, Yashtimadhu or classical formulations may be considered by a qualified Ayurvedic doctor, but herbs should not be self-prescribed. Women with breast cancer history, hormone-sensitive conditions, thyroid disease, liver disease, autoimmune disease, anticoagulant use, multiple medicines or planned surgery should seek medical advice before taking herbs.
NICE warns that the safety, quality and purity of unregulated complementary preparations may be uncertain, and interactions may occur [2]. Therefore, the best integrative care is transparent. The medical doctor should know what herbs or supplements the patient is taking, and the Ayurvedic doctor should know the patient’s medical history and medications.
The bottom line
Menopause hormone research has matured. HRT is not a miracle cure, and it is not a danger for every woman. It is a powerful medical option that works best when it is personalised.
For many healthy symptomatic women under 60 or within 10 years of menopause, HRT can significantly reduce hot flashes, hot flushes, night sweats, sleep disruption and vaginal symptoms, while supporting bone health [1]. For women who cannot or prefer not to use hormones, newer non-hormonal options such as fezolinetant and elinzanetant, as well as CBT, pelvic care, vaginal moisturisers, yoga and lifestyle medicine, can still offer meaningful relief [4,5,6].
Ayurveda’s role is not to compete with menopause hormone therapy. Its strength is to make menopause care more complete and compassionate. Ayurveda supports sleep, digestion, dryness, stress, nervous system steadiness, daily rhythm and graceful ageing. Modern medicine can offer targeted relief and safety screening. Together, they can help a woman move through menopause with confidence, privacy, dignity and strength.
A woman should not be told to suffer silently. She should not be frightened by outdated fear. She should not be pushed into treatment without understanding. She should be heard, assessed and offered safe choices.
Medical note: This article is educational and should be reviewed by a licensed menopause clinician before publication. Patients should consult a qualified healthcare professional before starting, stopping or combining HRT, non-hormonal medicines, supplements, herbs or Ayurvedic treatments.
References
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. This position statement explains HRT/MHT benefits, risks, timing, route, dose and personalisation.
https://www.menopause.org.au/health-professionals/position-statements/nams-2022-hormone-therapy-position-statement/ - NICE Guideline NG23: Menopause: identification and management. This UK guidance covers diagnosis, HRT, vaginal oestrogen, CBT, contraindications, transdermal HRT and complementary therapy cautions.
https://www.nice.org.uk/guidance/ng23/chapter/recommendations - Manson JE, Crandall CJ, Rossouw JE, et al. The Women’s Health Initiative Randomized Trials and Clinical Practice: A Review. JAMA. 2024. This review clarifies WHI findings and supports symptom treatment in appropriate early-menopause patients.
https://jamanetwork.com/journals/jama/fullarticle/2818206 - U.S. FDA: FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause. This source announces FDA approval of fezolinetant, a non-hormonal NK3 receptor antagonist for vasomotor symptoms.
https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause - U.S. FDA Prescribing Information: Lynkuet, elinzanetant. This FDA label lists elinzanetant for moderate to severe vasomotor symptoms due to menopause.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219469s000lbl.pdf - NICE Technology Appraisal TA1143: Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause. This 2026 guidance covers fezolinetant use when HRT is unsuitable.
https://www.nice.org.uk/guidance/ta1143 - KK Women’s and Children’s Hospital Singapore: Singapore’s first Menopause Management Guidelines. This source confirms Singapore’s 2026 guideline launch and its reaffirmation of MHT safety and efficacy in appropriate care.
https://www.kkh.com.sg/news/announcements/kkh-mchri-launches-singapore-s-first-set-of-menopause-management - Canadian Menopause Society Pocket Guide. This guide summarizes menopause management recommendations, including the usual timing window for initiating hormone therapy.
https://www.canadianmenopausesociety.org/sites/default/files/pdf/publications/Final-Pocket%20Guide.pdf - Health Canada: Summary Basis of Decision for Lynkuet. This source explains Health Canada authorisation of Lynkuet, elinzanetant, for moderate to severe vasomotor symptoms associated with menopause.
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1760450740287 - Støer NC, et al. Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway. British Journal of Cancer. 2024. This study examines breast cancer risk by hormone therapy type and route.
https://www.nature.com/articles/s41416-024-02590-1 - American College of Obstetricians and Gynecologists: Postmenopausal Estrogen Therapy Route of Administration and Risk of Venous Thromboembolism. This source discusses oral versus transdermal estrogen and clot risk.
https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2013/04/postmenopausal-estrogen-therapy-route-of-administration-and-risk-of-venous-thromboembolism - Charaka Samhita, Sutra Sthana, Chapter 1, Deerghanjiviteeya Adhyaya, Text 41. This classical verse defines the scope of Ayurveda as knowledge of beneficial and harmful life.
https://www.carakasamhitaonline.com/index.php/Deerghanjiviteeya_Adhyaya - Charaka Samhita, Chikitsa Sthana, Chapter 1, Rasayana Adhyaya, Texts 7–8. This section explains Rasayana and its traditional rejuvenative aims.
https://www.carakasamhitaonline.com/index.php/Rasayana_Adhyaya - Pingali U, Nutalapati C, Wang Y. Ashwagandha and Shatavari Extracts Dose-Dependently Reduce Menopause Symptoms, Vascular Dysfunction, and Bone Resorption in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Menopausal Medicine. 2025.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12070120/ - Ademola J, et al. Efficacy and safety of Shatavari root extract for menopausal symptoms: a randomized, double-blind, three-arm, placebo-controlled study. Frontiers in Reproductive Health. 2025.
https://www.frontiersin.org/journals/reproductive-health/articles/10.3389/frph.2025.1654503/full - Wang H, et al. The effectiveness of yoga on menopausal symptoms: a systematic review and meta-analysis of randomized controlled trials. International Journal of Nursing Studies. 2025.
https://pubmed.ncbi.nlm.nih.gov/39467491/ - Ashtanga Hridaya, Sutra Sthana, Chapter 2, Dinacharya Adhyaya, Text 8. This classical passage describes Abhyanga and its traditional benefits for Vata, sleep, fatigue and ageing support.
https://www.easyayurveda.com/ayurvedic-daily-routine-ashtanga-hrudaya-sutra-sthana-chapter-2/
